AGIO.US.EQUI (AGIO.US.EQUI) News
Follow AGIO.US.EQUI (AGIO.US.EQUI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
H.C. Wainwright sees FDA Priority Review as positive signal for Agios' mitapivat
H.C. Wainwright analyst Emily Bodnar notes that Agios Pharmaceuticals announced that the FDA accepted its sNDA for mitapivat, in sickle cell disease under the accelerated approval pathway with a Priority Review and a PDU
EQUITY | Jul 07, 2026, 03:24 PM UTC
L
Agios Pharmaceuticals granted priority review for mitapivat sNDA
Agios Pharmaceuticals announced that the FDA has accepted its supplemental new drug application for mitapivat, an oral pyruvate kinase activator, in sickle cell disease with a priority review. The Prescription Drug User
EQUITY | Jul 07, 2026, 11:11 AM UTC